Clinical trials: Papillary Thyroid Carcinoma
Head and Neck Cancer
High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid Cancer
RATIONALE: Radioactive iodine uses radiation to kill tumor cells. Giving iodine I 131 with or without thyroid-stimulating hormone after surgery may kill any tumor cells that remain after surgery.
- Trial name
- HiLo (NCT00415233)
- Testing
- recombinant thyroid-stimulating hormone, Radiodine ablation without rhTSH
- Where
- 25 sites in United Kingdom
- Volunteers
- 438 people
- Sponsor
- University College, London
Head and Neck Cancer
Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer
RATIONALE: Celecoxib may stop the growth of thyroid cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth.
- Trial name
- NCT00061906
- Testing
- celecoxib
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Thyroid Cancer, Regret
Regret Emotion After Thyroidectomy in Low-Risk Papillary Thyroid Cancer
This randomized, active-controlled, non-inferiority trial is scheduled to begin in May 2025 and will continue until June 2027. Inclusion criteria: (1) Patients with low-risk papillary thyroid cancer without lymph node metastasis…
- Trial name
- NCT06804863
- Testing
- Postoperative Regret Reduction through Immediate Quality of Life Intervention
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- West China Hospital
Thyroid Neoplasms, Thyroid Cancer
Sentinel Lymphnode in Patients With Papillary Thyroid Carcinoma and in Patients With Suspected Thyroid Neoplasia
The standard surgical treatment for highly differentiated papillary thyroid cancer > 10 mm according to recent national and international guidelines, is total thyroidectomy and central lymphnode clearance, and for patients with…
- Trial name
- SNTC (NCT01089335)
- Testing
- Histological investigation of the SN
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Region Skane
Drainage, Thyroid Cancer
No Drainage During Transoral Endoscopic Thyroidectomy Vestibular Approach(TOETVA)
This study evaluates the viability and safety of no drainage tube placement during transoral endoscopic thyroidectomy vestibular approach in treatment of patients with papillary thyroid carcinoma.
- Trial name
- NCT04931576
- Testing
- no drainage tube applied
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Papillary Thyroid Carcinoma
Single-Incision Gasless Endoscopic Total Thyroidectomy Via Subclavian Approach Versus Open Surgery for PTC
Historically, performing a contralateral thyroid lobectomy and lymph node dissection via the subclavian approach was considered challenging.
- Trial name
- NCT06592755
- Testing
- single-incision, gasless endoscopic total thyroidectomy with central compartment neck dissection, conventional open surgery
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Papillary Thyroid Cancer
Percentage of BRAFV600E Alleles and Outcome in Thyroid Carcinoma
BRAFV600E is the most frequent oncogene in Papillary thyroid carcinoma (PTC). It correlates with greater extension, lymph node metastasis, and advanced stage.
- Trial name
- ABOUT (NCT04664413)
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- University of Salerno
Thyroid Papillary Carcinoma
Prospective Study on the Clinical Prognosis of Bilateral Central Lymph Node Dissection in the Patients With Unilateral Thyroid Papillary Carcinoma
This study recruit the patients with unilateral papillary thyroid cancer before operation,the patients agree to enter the test,and divided into experimental and control group.experimental group patients receive the surgery…
- Trial name
- NCT02648399
- Testing
- surgery：BCND（bilateral central lymph node dissection）, surgery：UCND（unilateral central lymph node dissection）
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Fujian Medical University
Thyroid Gland Follicular Carcinoma, Thyroid Gland Papillary Carcinoma
Health and Wellness Coaching to Improve Adherence to Healthy Habits and Treatment Plans in Papillary and Follicular Thyroid Cancer Survivors
This clinical trial evaluates the impact of a patient-centered health and wellness coaching (HWC) intervention on adherence to treatment plans and healthy lifestyle practices in patients with papillary or follicular thyroid…
- Trial name
- NCT07545837
- Testing
- Counseling, Interview, Questionnaire Administration
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Recurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer
Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer
This phase II trial is studying how well tanespimycin works in treating patients with inoperable locoregionally advanced or metastatic thyroid cancer.
- Conditions
- Recurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer, Thyroid Gland Medullary Carcinoma
- Trial name
- NCT00118248
- Testing
- tanespimycin
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer
Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer
This phase II trial studies how well giving sunitinib malate works in treating patients with iodine-refractory recurrent or metastatic thyroid cancer.
- Conditions
- Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer, Stage IVA Papillary Thyroid Cancer, Stage IVB Follicular Thyroid Cancer
- Trial name
- NCT00519896
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Washington
Papillary Thyroid Cancer
Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma
Primary objective: The 3-years disease-free survival was compared between low-dose group (30 mCi) and high-dose group (100 mCi).
- Trial name
- NCT04354324
- Testing
- Radioiodine
- Where
- China
- Volunteers
- 254 people, healthy volunteers welcome
- Sponsor
- Zhujiang Hospital
Anaplastic Thyroid Cancer, Insular Thyroid Cancer
Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
Phase II trial to study the effectiveness of sorafenib tosylate in treating patients who have locally advanced, metastatic, or locally recurrent thyroid cancer.
- Conditions
- Anaplastic Thyroid Cancer, Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage III Follicular Thyroid Cancer
- Trial name
- NCT00095693
- Testing
- sorafenib tosylate, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Head and Neck Cancer
Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases
RATIONALE: Diagnostic procedures using boronophenylalanine-fructose complex (BPA-F) and/or sodium borocaptate (BSH) to detect the presence of boron in tumor cells may help determine whether patients who have thyroid cancer, head…
- Conditions
- Colorectal Cancer, Head and Neck Cancer, Metastatic Cancer
- Trial name
- NCT00062348
- Testing
- boronophenylalanine-fructose complex, sodium borocaptate, conventional surgery
- Where
- Germany
- Volunteers
- 27 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Thyroid Carcinoma
Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma
This study is to evaluate the effectiveness of nsPFA in treating papillary thyroid microcarcinoma. T
- Trial name
- NCT07218315
- Testing
- CellFX nsPFA Percutaneous Electrode System
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Papillary Thyroid Cancer
The Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma
1. To evaluate the clinical outcomes of ultrasound-guided thermal ablation and thyroid surgery for the treatment of papillary thyroid carcinoma; 2.
- Trial name
- NCT06316895
- Testing
- thyroid surgery, ultrasound-guided thermal ablation
- Where
- China
- Volunteers
- 3,772 people
- Sponsor
- Chinese PLA General Hospital
Breast Cancer, Cholangiocarcinoma
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion.
- Conditions
- Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms
- Trial name
- STARTRK-2 (NCT02568267)
- Testing
- Entrectinib
- Where
- 120 sites in United States, Australia and 14 more
- Volunteers
- 534 people
- Sponsor
- Hoffmann-La Roche
Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
This phase II trial tests how well vemurafenib and cobimetinib work in treating patients with high risk differentiated thyroid carcinoma with BRAFV600E mutation, in preparation for radioactive iodine therapy.
- Conditions
- Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma, Thyroid Gland Papillary Carcinoma
- Trial name
- NCT06440850
- Testing
- Biospecimen Collection, Cobimetinib, Computed Tomography
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- City of Hope Medical Center
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of TY-1091 in Patients With Advanced Solid Tumors
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of TY-1091 administered orally in…
- Conditions
- RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer, Neoplasms
- Trial name
- NCT05675605
- Testing
- TY-1091
- Where
- China
- Volunteers
- 248 people
- Sponsor
- TYK Medicines, Inc
Thyroid Cancer, Papillary, Primary Aldosteronism
Clinical and Genetic Investigation of the Association Between Primary Aldosteronism and Thyroid Cancer
Aldosterone excess can cause oxidative stress leading to DNA damage in vitro and in vivo. Single case reports demonstrated a coincidence of primary aldosteronism (PA) with different malignancies.
- Trial name
- NCT06068101
- Testing
- Secreening test for primary aldosteronism and Confirmatory Testing
- Where
- Brazil
- Volunteers
- 274 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo